Literature DB >> 30718255

In Vitro Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria.

Evelyne Lacasse1, Eric Brouillette1, Audrey Larose1, Thomas R Parr2, Aileen Rubio2, François Malouin3.   

Abstract

Tebipenem (SPR859) is the microbiologically active form of SPR994 (tebipenem-pivoxil), an orally available carbapenem with activity against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae Measurement of the relative binding of SPR859 to the bacterial cell targets revealed that it is a potent inhibitor of multiple penicillin-binding proteins (PBPs) but primarily a Gram-negative PBP 2 inhibitor, similar to other compounds in this class. These data support further clinical development of SPR994.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  PBP; carbapenems; penicillin-binding proteins; tebipenem

Mesh：

Substances：

Year:  2019        PMID： 30718255      PMCID： PMC6437484          DOI： 10.1128/AAC.02181-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins.

Authors:  G Zhao; T I Meier; S D Kahl; K R Gee; L C Blaszczak
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity.

Authors:  M Hikida; K Itahashi; A Igarashi; T Shiba; M Kitamura
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Function of penicillin-binding protein 2 in viability and morphology of Pseudomonas aeruginosa.

Authors:  Blaine A Legaree; Kathy Daniels; Joel T Weadge; Darrell Cockburn; Anthony J Clarke
Journal:  J Antimicrob Chemother       Date:  2007-02-08       Impact factor: 5.790

4.  Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.

Authors:  Y Yang; N Bhachech; K Bush
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

Review 5.  Tebipenem, the first oral carbapenem antibiotic.

Authors:  Akash Jain; Luke Utley; Thomas R Parr; Thomas Zabawa; Michael J Pucci
Journal:  Expert Rev Anti Infect Ther       Date:  2018-07-27       Impact factor: 5.091

6.  Crystal structures of biapenem and tebipenem complexed with penicillin-binding proteins 2X and 1A from Streptococcus pneumoniae.

Authors:  Mototsugu Yamada; Takashi Watanabe; Nobuyoshi Baba; Yasuo Takeuchi; Fukuichi Ohsawa; Shuichi Gomi
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

7.  Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.

Authors:  Todd A Davies; Wenchi Shang; Karen Bush; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2008-02-04       Impact factor: 5.191

8.  Penicillin binding protein 2 is dispensable in Escherichia coli when ppGpp synthesis is induced.

Authors:  D Vinella; R D'Ari; A Jaffé; P Bouloc
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

9.  The mecillinam resistome reveals a role for peptidoglycan endopeptidases in stimulating cell wall synthesis in Escherichia coli.

Authors:  Ghee Chuan Lai; Hongbaek Cho; Thomas G Bernhardt
Journal:  PLoS Genet       Date:  2017-07-27       Impact factor: 5.917

10.  Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria.

Authors:  Abdelhamid Asli; Eric Brouillette; Kevin M Krause; Wright W Nichols; François Malouin
Journal:  Antimicrob Agents Chemother       Date:  2015-11-16       Impact factor: 5.191
View more
  6 in total

1.  In Vitro and In Vivo Characterization of Tebipenem, an Oral Carbapenem.

Authors:  Nicole Cotroneo; Aileen Rubio; Ian A Critchley; Chris Pillar; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

2.  In Vitro and In Vivo Characterization of Tebipenem (TBP), an Orally Active Carbapenem, against Biothreat Pathogens.

Authors:  Nicholas P Clayton; Akash Jain; Stephanie A Halasohoris; Lisa M Pysz; Sanae Lembirik; Steven D Zumbrun; Christopher D Kane; Michael J Hackett; Denise Pfefferle; M Autumn Smiley; Michael S Anderson; Henry Heine; Gabriel T Meister; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.191

3.  The Class A β-Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States.

Authors:  Scott A Becka; Elise T Zeiser; John J LiPuma; Krisztina M Papp-Wallace
Journal:  Antibiotics (Basel)       Date:  2022-05-17

4.  Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Tebipenem Pivoxil Hydrobromide on QT/QTc Intervals in Healthy Subjects.

Authors:  Vipul K Gupta; Gary Maier; Paul Eckburg; Lisa Morelli; Yang Lei; Akash Jain; Erika Manyak; David Melnick
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

5.  Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment.

Authors:  Gina Patel; Keith A Rodvold; Vipul K Gupta; Jon Bruss; Leanne Gasink; Floni Bajraktari; Yang Lei; Akash Jain; Praveen Srivastava; Angela K Talley
Journal:  Antimicrob Agents Chemother       Date:  2022-04-14       Impact factor: 5.191

6.  Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects.

Authors:  Paul B Eckburg; Akash Jain; Susannah Walpole; Grayson Moore; Luke Utley; Erika Manyak; Aaron Dane; David Melnick
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.